Tyrosine kinases (TKs) are a family of proteins that play a key role in themost fundamental cellular processes including the cell cycle, proliferation, differentiation, cell death and survival and are crucial inoncogenesis. Tyrosinekinase inhibitors (TKIs) actby inhibiting the catalytic subunit of TKs. Clinical trials in several cancer types have established the role of these drugs in cancer therapeutics. Although TKIs are “targeted therapeutics,”many inhibit a range of kinase receptorswithvariedpotencyand selectivity. Targeted receptors include vascular endothelial growth factor receptor (VEGFR), platelet-derivedgrowthfactor receptors (PDGFRs), fibroblastgrowth factor receptor (FGFR), epidermal growth factor receptor (EGFR), c-KIT, FLT-3, c-MET, MEK, BRAF, and insulin-like growth factor receptor (IGFR).1 Tyrosinekinase inhibitors causeaspectrumofdermatologic adverse events that has been described as a “class effect.” These adverse effects include rash, hand-foot-skin reaction (HFSR), alopecia, depigmentation, pruritus, xerosis, acneiform rashes, scrotal lesions, andmucositis. The distinctmultikinase inhibition profile of TKIs produces a different constellation of these cutaneous adverse events (CEs).2 Despite this spectrum,many phase 3 trials involving TKIs reportedCEscollectivelyas “skin toxicity.”There isclearlyaneed forgreaterdetail anddescriptionsof therangeofCEsrelatedtothese agents. In support of this, one meta-analysis2 focusing on CEs reportedonlyonHFSR, andpruritus. Toelucidate the full potential diversity of CEs, 2 small prospective trials3,4 with sorafenib and sunitinib, respectively, were designed. Zuo et al report the incidence of CEs in patients treated with cabozantinib administered at a dose of 60 mg/d continuously in metastatic urothelial carcinomabymeans of dedicated history and physical examination.Adermatologist reviewedpatientsonlywhen signs and symptoms of skin toxicity were present. Cabozantinib is a potent, small-molecule, oral multi-TKI targeting VEGFR2, c-MET, RET, c-KIT, AXL, and FLT3. In 2012, the US Food andDrug Administrationapprovedcabozantinib for the treatmentofmetastaticmedJAMADERMATOLOGY